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Highlights 
x Treatment with antibiotic combinations offers the possibility of synergistic 
killing. 
x In vitro observed synergy was validated in vivo using a Galleria mellonella 
model. 
x Rifampicin-based combinations proved useful against selected resistant 
enterococci. 
ABSTRACT 
Enterococci are a leading cause of healthcare-associated infection worldwide and 
display increasing levels of resistance to many of the commonly used antimicrobials, 
making treatment of their infections challenging. Combinations of antibiotics are 
occasionally employed to treat serious infections, allowing for the possibility of 
synergistic killing. The aim of this study was to evaluate the effects of different 
antibacterial combinations against enterococcal isolates using an in vitro approach 
and an in vivo Galleria mellonella infection model. Five Enterococcus faecalis and 
three Enterococcus faecium strains were screened by paired combinations of 
rifampicin, tigecycline, linezolid or vancomycin using the chequerboard dilution 
method. Antibacterial combinations that displayed synergy were selected for in vivo 
testing using a G. mellonella larvae infection model. Rifampicin was an effective 
antibacterial enhancer when used in combination with tigecycline or vancomycin, 
with minimum inhibitory concentrations (MICs) of each individual antibiotic being 
reduced by between two and four doubling dilutions, generating fractional inhibitory 
concentration index (FICI) values between 0.31 and 0.5. Synergy observed with the 
chequerboard screening assays was subsequently observed in vivo using the G. 
mellonella model, with combination treatment demonstrating superior protection of 
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larvae post-infection in comparison with antibiotic monotherapy. In particular, 
rifampicin in combination with tigecycline or vancomycin significantly enhanced 
larvae survival. Addition of rifampicin to anti-enterococcal treatment regimens 
warrants further investigation and may prove useful in the treatment of enterococcal 
infections whilst prolonging the clinically useful life of currently active antibiotics. 
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1. Introduction 
Enterococci cause a range of infections from uncomplicated urinary tract infection to 
life-threatening endocardial and device-related infections. These pathogens are 
intrinsically resistant to a number of commonly used antimicrobials and have a 
remarkable ability to acquire new resistance mechanisms. This situation has fuelled 
global concern over future treatment options for serious enterococcal infections 
caused by multidrug-resistant strains. 
 
Antibacterial agents commonly utilised or recently developed for the treatment of 
enterococcal infections include vancomycin, linezolid, daptomycin, telavancin and 
dalbavancin. Tigecycline has been suggested as an alternative therapy but, with the 
exception of intra-abdominal infections, a current lack of clinical data has impeded 
greater use [1]. As resistance to many of these antibacterials increases, including 
tigecycline [2], therapeutic options become progressively more limited and the need 
for strategies to protect against further loss of activity becomes paramount. 
 
Prescribing antibacterial combinations is established clinical practice for the 
treatment of serious infections. There are several potential advantages to combined 
therapy: an enhanced killing effect and the possibility of synergy; a reduction in the 
concentration of individual agents required (reduced toxicity and selection pressure); 
and, of vital importance, the ability to protect against the development of resistance. 
For example, daptomycin is recommended as part of a combined therapy for serious 
infections [3,4]. Rifampicin is rapidly bactericidal against many Gram-positive 
bacteria and displays good tissue penetration, but the rapid development of 
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resistance precludes its use as monotherapy [4], leading to this old agent often being 
considered specifically for use in combination therapy [5,6]. 
 
The aim of this study was to describe the killing effect of different antibacterial 
combinations against clinical enterococcal isolates using standard methods and in 
an in vivo Galleria mellonella infection model. 
 
2. Materials and methods 
2.1. Bacterial isolates and growth conditions 
Eight enterococcal isolates were studied, including three vancomycin-sensitive 
strains [Enterococcus faecalis ATCC 29212 and E. faecalis clinical isolates E019 
and E045] and four vancomycin-resistant strains [E. faecalis ATCC 51299, 
Enterococcus faecium ATCC 51559 and E. faecium clinical isolates E022 and E039] 
and one vancomycin-sensitive tigecycline-resistant E. faecalis UW6940 (supplied by 
Dr Werner, Centre for Diagnostic Medicine, Germany) (Table 1). 
 
2.2. Preparation of antibiotics 
Vancomycin and rifampicin were purchased from Sigma-Aldrich (Dorset, UK). 
Linezolid and tigecycline were gifted from Pfizer Ltd. (Surrey, UK). Antibiotic stocks 
of 10 000 mg/L (except linezolid, 1000 mg/L) were freshly prepared using distilled 
water each day (linezolid and tigecycline) or were stored at ±20 qC for a maximum of 
1 week (vancomycin and rifampicin). 
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2.3. Antibiotic susceptibility testing 
Minimum inhibitory concentrations (MICs) of antibiotics were determined by the broth 
microdilution method described by the British Society for Antimicrobial 
Chemotherapy (BSAC) for each of the eight isolates [7]. Enterococcus faecalis 
ATCC 29212 was included as a control strain in each experiment, and all results 
were within guideline limits. MIC determinations were performed in duplicate and 
were repeated on two further occasions. 
 
2.4. Antibacterial combination assays 
Standard chequerboard assays were performed in 96-well microtitre plates (Sterilin 
Ltd., Gwent, UK) with doubling dilutions of each antibiotic prepared in Mueller±Hinton 
broth (Oxoid Ltd., Basingstoke, UK). The final sub-MIC ranges used for vancomycin, 
rifampicin, tigecycline and linezolid were 0.12±1024, 0.12±32, 0.007±4 and 0.12±8 
mg/L, respectively. An equal volume of standardised bacterial suspension of 5 u 105 
CFU/mL was added and the plates were incubated at 37 qC in air for 24 h. Fractional 
inhibitory concentrations (FICs) were calculated as the MIC of drug A or B in 
combination divided by the MIC of drug A or B alone, respectively, and the FIC index 
(FICI) was obtained by adding the two FIC values. The drug combination that 
consistently generated the lowest FICI after repeating the experiment in duplicate on 
two further occasions was used to categorise the results as follows: FICIs of d0.5 
were interpreted as synergistic; FICIs of >0.5 but <4 were considered as no 
interaction; and FICIs t4 were interpreted as antagonistic [8]. Combinations 
demonstrated to be synergistic were assessed using the G. mellonella infection 
model. 
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2.5. Galleria mellonella infection model 
Galleria mellonella wax moth larvae (Livefood UK Ltd., Rooks Bridge, UK) in their 
final instar stage of development were stored at room temperature in the dark and 
were used within 1 week of delivery. Healthy larvae, without grey markings and of a 
similar weight (200±300 mg), were selected and split into experimental groups of 15 
larvae [9]. Bacterial suspensions of each isolate were prepared based on a pre-
optimised dose (1 u 106±5 u 106 CFU/larva) that caused >80% larvae deaths at 72 h 
post-infection (Supplementary Fig. S1). 
 
After sterilisation of the inoculation site with 70% (v/v) ethanol, the last right proleg 
was used to deliver 10 PL of bacterial suspension (as recorded in Fig. 1) into the 
haemocoel (primary body cavity) using a 1/2 inch, 30 G needle (BD Precisionglide® 
syringe needle; Sigma) attached to a 50 PL Hamilton syringe (1705 TLL; Jaytee 
Biosciences Ltd., Herne Bay, UK). Antimicrobial drugs (used at 1u MIC as 
monotherapy or between 1/4u MIC and 1/16u MIC for antibacterial combinations) 
were delivered into the haemocoel via a 10 PL injection into the last left proleg (n = 
15). Larvae were incubated in vented plastic Petri dishes at 37 qC in air and deaths 
were scored through observation of melanisation and failure of larvae to move in 
response to touch at the time points 12, 24, 48, 72 and 96 h. Appropriate uninfected 
and vehicle controls were included for each experiment. 
 
Pooled data from three independent experiments, using G. mellonella larvae 
obtained from different batches, were assessed using the Kaplan±Meier method, 
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and treatment groups were compared by the log-rank (Mantel±Cox) test using 
GraphPad Prism® 6 (GraphPad Software Inc., La Jolla, CA). P-values of <0.05 were 
considered statistically significant. 
 
3. Results 
3.1 Assessing the in vitro antimicrobial sensitivities of eight enterococcal isolates 
using the chequerboard dilution method 
The results of susceptibility testing are shown in Table 1. No antimicrobial 
combination showed an antagonistic effect against any of the strains evaluated. Of 
the six antimicrobial combinations tested against eight strains, synergy was seen in 
six cases, but in each case it was a rifampicin-containing combination. Synergy was 
demonstrated against all vancomycin-resistant enterococci by at least one 
rifampicin-containing antibacterial combination (all E. faecium isolates and one E. 
faecalis isolate) (Tables 1 and 2). 
 
3.2. Antimicrobial treatment of infected Galleria mellonella larvae 
Dose-dependent killing of G. mellonella was achieved when larvae were infected 
with 1 u 106, 3 u 106 or 5 u 106 CFU/larva of each isolate. Enterococcus faecalis 
ATCC 51299 was highly virulent at all three doses tested, whilst E. faecium ATCC 
51559, E. faecium E022 and E. faecium E039 were less virulent in the G. mellonella 
model (Supplementary Fig. S1). 
 
Treatment of infected larvae with an antibacterial combination of sub-MIC agents 
consistently led to an increased level of survival (20±73% larvae survival at 96 h, 
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with a median value of 57%) compared with those treated with a higher 
concentration of a single agent (7±53% survival, with a median value of 13%) (Fig. 
1). A statistically significant greater level of survival was observed with four of the six 
combinations tested compared with the untreated control group (Fig. 1a,c,e,f), whilst 
only two vancomycin monotherapies administered at 1u MIC significantly improved 
survival of G. mellonella compared with the control group (Fig. 1c; P = 0.003; Fig. 1e, 
P = 0.0159). Furthermore, the combination of rifampicin with tigecycline was 
statistically superior to tigecycline alone (13% larval survival when treated with 
tigecycline for infection with strain E039 vs. 60% larval survival when treated with the 
antimicrobial combination; P = 0.0237) (Fig. 1f). 
 
4. Discussion 
Antibacterial combinations are often utilised during treatment of serious infections, 
but the superiority of one antibiotic combination over another for the treatment of 
enterococcal infections remains unproven. In this study, it was demonstrated that 
antimicrobial combinations including rifampicin can be synergistic against 
enterococci, but this is not a consistent finding among enterococci. 
 
Although traditionally used in the investigation of antibacterial combinations for 
synergistic activity, chequerboard assays have reproducibility issues and may not 
adequately reflect activity in vivo. The in vivo G. mellonella infection model, however, 
shares some basic immunity characteristics with mammals, including the deployment 
of proteolytic cascades (clotting and melanisation) following pathogen recognition 
[10]. An additional advantage, and in contrast to mammalian models, G. mellonella 
can be inexpensively sourced and is not subject to animal research legislature [11]. 
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In this study, the larval model corroborated the in vitro data. Treatment with 
antibacterial combinations that were synergistic in vitro improved the survival rate of 
larvae compared with those treated with a single agent. 
 
All combinations where synergy was detected were performed with concentrations of 
antibacterial below the MIC (1/4u to 1/16u MIC) and contained rifampicin, with 
rifampicin with either vancomycin or tigecycline being the most effective 
combinations. Of the five vancomycin or tigecycline combinations trialled, a 
statistically greater proportion of the larvae treated with combination therapy survived 
in four of the assays compared with wax moths that were either untreated or 
received only one antibiotic. 
 
Rifampicin is effective against a range of Gram-positive pathogens, but the rapid 
development of resistance necessitates that it be used in combination with another 
agent. Several studies have highlighted the synergistic activity of rifampicin with 
others agents [6,12]; indeed, rifampicin-based combinations, including vancomycin, 
are recommended for the treatment of staphylococcal endocarditis [3]. Combinations 
incorporating rifampicin are not, however, in routine use for treatment of 
enterococcal infections. 
 
The classic combination of a cell-wall-active agent (such as vancomycin or a E-
lactam) plus an aminoglycoside results in a synergistic effect against enterococci 
[13]. High-level aminoglycoside resistance has, however, led to a reconsideration of 
this standard treatment (gentamicin and ampicillin) resulting, in some instances, in 
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the recommendation of an unusual double E-lactam combination (ampicillin plus 
ceftriaxone) [14,15]. In addition, the continual rise of vancomycin resistance has 
limited the value of this agent in classic treatment and, as a consequence, excluded 
it in many instances from combination therapy studies. Yet a vancomycin-based 
combination has shown efficacy against resistant enterococci [16]. In the current 
study, a vancomycin plus rifampicin combination improved the survival rate of G. 
mellonella larvae infected with selected rifampicin- and/or vancomycin-resistant 
enterococcal strains. 
 
Typically, the interaction of tigecycline with other agents results in indifference or 
occasionally antagonism, an exception being with rifampicin [17]. High rates of in 
vitro synergism have been described for tigecycline plus rifampicin against E. 
faecalis and E. faecium isolates using the chequerboard dilution method [5,18]. More 
recently, Silvestri et al. tested tigecycline plus rifampicin combinations in an animal 
model of surgical wound infections and reported good activity against enterococcal 
isolates [19], supporting the observations reported here with the wax moth infection 
model. 
 
The failure to assess any reduction in susceptibility to agents during treatment was a 
limitation of the current study, since the rapid development of resistance against 
rifampicin in particular will always remain a concern and the observations of 
Holmberg and Rasmussen indicate that combined therapy might not be sufficient to 
prevent this from developing [20].  
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In conclusion, the study has revealed the efficacy of rifampicin-based combination 
therapies against some highly-resistant enterococci, and further investigation in vivo 
with additional clinically relevant strains is warranted. 
 
Antibiotic combinations offer the potential to treat problematic antimicrobial-resistant 
bacteria with lower concentrations of antibiotic without compromising efficacy and 
with a lower risk of adverse side effects. Moreover, combination therapy has the 
potential to reduce selective pressure and to help protect the clinical life of agents, 
particularly newer agents for which little, if any, resistance exists. In addition, the 
chequerboard assay remains a useful screening tool for the detection of potentially 
synergistic antimicrobial combinations, with the wax moth model being a practical 
and superior technique for providing quantitative in vivo data. 
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Fig. 1. Effect of antibiotic treatment on survival of Galleria mellonella larvae infected 
with (a) Enterococcus faecalis ATCC 51299, (b) Enterococcus faecium ATCC 51559, 
(c,d) E. faecium E022 and (e,f) E. faecium E039 (n = 45). MIC, minimum inhibitory 
concentration; VAN, vancomycin; RIF, rifampicin; LZD, linezolid; TGC, tigecycline. 
*** P < 0.001; ** P < 0.01; * P < 0.05 for tested antibiotic combinations compared 
with the untreated control; ^ P < 0.05 for tested antibiotic combinations compared 
with tigecycline alone. 
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Table 1. Standard antibiotic susceptibility and antibacterial combination results for eight enterococcal isolates 
Enterococcal isolate MIC (mg/L) a Lowest FICI generated by each drug combination b 
VAN RIF LZD TGC VAN + TGC VAN + RIF TGC + RIF LZD + VAN LZD + TGC LZD + RIF 
E. faecalis ATCC 29212 2 2 2 0.12 0.62 0.62 0.62 1 1 0.62 
E. faecalis E019 1 4 2 0.25 1 1 0.75 1 1 0.62 
E. faecalis E045 2 1 2 0.12 0.75 0.75 0.75 1.5 1 0.75 
E. faecalis ATCC 51299 64 1 1 0.12 0.62 0.37 0.75 0.75 0.75 0.62 
E. faecalis UW6940 1 2 1 2 0.75 1 0.75 1 0.75 0.75 
E. faecium ATCC 51559 256 8 2 0.12 1 0.75 0.62 0.56 0.75 0.5 
E. faecium E022 512 4 1 0.12 0.62 0.37 0.5 0.56 0.56 0.62 
E. faecium E039 512 16 2 0.12 0.75 0.31 0.37 0.62 0.75 0.62 
MIC, minimum inhibitory concentration; VAN, vancomycin; RIF, rifampicin; LZD, linezolid; TGC, tigecycline; FICI, fractional 
inhibitory concentration index. 
a $QWLELRWLFVXVFHSWLELOLW\EUHDNSRLQWV9$15,)DQG/='VHQVLWLYHPJ/UHVLVWDQW>4 mg/L; 7*&VHQVLWLYHPJ/
intermediate 0.5 mg/L, resistant >0.5 mg/L. 
b ,PSDFWRIDQWLEDFWHULDOFRPELQDWLRQVV\QHUJ\),&,VKRZQLQEROGQRLQWHUDFWLon, FICI >0.5 to <4; and antagonism t4. 
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Table 2. Enterococcal strains displaying synergy with antibiotic combinations 
Enterococcal 
isolate 
Antibiotic (drug A) synergistic 
combination with RIF 
MIC of drug A and RIF 
alone (mg/L) 
Concentration of the drug in 
combination (mg/L) 
FIC FICI 
Drug A RIF Drug A RIF Drug 
A 
RIF 
E. faecalis ATCC 
51299 
VAN 64 1 16 0.12 0.25 0.12 0.37 
E. faecium ATCC 
51559 
LZD 2 8 0.5 2 0.25 0.25 0.5 
E. faecium E022 VAN 512 4 64 1 0.125 0.25 0.37 
TGC 0.12 4 0.03 1 0.25 0.25 0.5 
E. faecium E039 VAN 512 16 128 1 0.25 0.06 0.31 
TGC 0.12 16 0.03 2 0.25 0.12 0.37 
RIF, rifampicin; VAN, vancomycin; LZD, linezolid; TGC, tigecycline; MIC, minimum inhibitory concentration; FIC, fractional inhibitory 
concentration; FICI, fractional inhibitory concentration index. 
 
Page 19 of 19
